---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-22-000044"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:35:19.140473+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q3 commercial revenue $4.7M, net loss $16.3M, reaffirms FY2022 guidance

## Summary
- Commercial revenue $4.7M (down 25% YoY from $6.3M); recurring revenue up 34% to $2.9M.
- Placed 3 Growth Direct systems in Q3 vs 10 in prior year; validated 4 customer systems.
- Net loss $16.3M ($0.38/share) vs $25.0M ($0.71) in Q3 2021; ops expenses rose on strategic review and restructuring.
- Reaffirms FY2022 revenue at least $17M; expects at least 2 system placements in Q4.
- Cash $150.1M, no debt; strategic review ongoing; restructuring plan targets $8-9M annual savings by Q1 2023.

## SEC filing metadata
- accession: 0001380106-22-000044
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000044/0001380106-22-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000044/rpid-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-22-000044
- JSON: https://secwatch.observer/filing/0001380106-22-000044.json
- Plain text: https://secwatch.observer/filing/0001380106-22-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.